Department of Clinical Microbiology, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain.
Expert Opin Pharmacother. 2021 Apr;22(5):535-541. doi: 10.1080/14656566.2020.1867538. Epub 2021 Jan 4.
: Despite efforts to the contrary, tuberculosis remains one of the leading causes of death in the world. The appearance of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of has increased the need for new therapeutic options against these strains.: This review covers the susceptibility, pharmacokinetics, and pharmacodynamics of bedaquiline, a new drug shown to be active against resistant strains. The authors further review clinical data concerning its use against MDR and XDR strains, discussing recent clinical guidelines from different international societies.: Available data demonstrate the usefulness of bedaquiline against resistant . Despite the difficulty in analyzing multidrug therapies, the use of bedaquiline in MDR and XDR tuberculosis increases success rates, allowing shortened treatments and lower drug use than previously recommended regimens. Moreover, the fact that MDR and XDR strains are common in many places creates a need to include this drug in the currently available protocols. It is essential to overcome the substantial barriers that some countries encounter in obtaining bedaquiline, as doing so will make therapeutic regimens including this drug available for all patients.
尽管做出了种种努力，结核病仍然是世界上主要的死亡原因之一。耐多药（MDR）和广泛耐药（XDR）结核菌株的出现增加了对这些菌株的新治疗选择的需求。
本综述涵盖了贝达喹啉的药敏性、药代动力学和药效动力学，这是一种被证明对耐药菌株有效的新药。作者进一步综述了关于其在治疗 MDR 和 XDR 菌株方面的临床数据，讨论了来自不同国际协会的最新临床指南。
现有数据表明贝达喹啉对耐药结核分枝杆菌有用。尽管分析多药治疗存在困难，但贝达喹啉在 MDR 和 XDR 结核病中的应用提高了成功率，允许缩短治疗时间并降低药物使用量，低于以前推荐的方案。此外，MDR 和 XDR 菌株在许多地方很常见，这使得需要将这种药物纳入现有的方案中。克服一些国家在获得贝达喹啉方面遇到的巨大障碍至关重要，因为这样做将使包括这种药物在内的治疗方案能够为所有患者提供。
